These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31807168)

  • 1. Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III.
    Kawaguchi Y; Okano T; Imai K; Maehara S; Maeda J; Yoshida K; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Matsubayashi J; Ikeda N
    Oncol Lett; 2019 Dec; 18(6):6451-6458. PubMed ID: 31807168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
    Isaka T; Ito H; Nakayama H; Yokose T; Katayama K; Yamada K; Masuda M
    Mol Diagn Ther; 2019 Oct; 23(5):657-665. PubMed ID: 31347029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of platinum-based adjuvant chemotherapy for epidermal growth factor receptor-mutant lung adenocarcinoma.
    Onodera K; Yokota I; Matsumura Y; Hayasaka K; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
    J Thorac Dis; 2023 Dec; 15(12):6534-6543. PubMed ID: 38249908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
    Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
    Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Survival Outcomes Based on
    Yang XN; Yan HH; Wang J; Chu XY; Liu ZD; Shen Y; Ma HT; Fu XN; Hu J; Zhou NK; Liu YY; Zhou XM; Li JS; Yang K; Li J; Xu L; Wang SY; Wang Q; Liu LX; Xu S; Chen ZY; Lou HH; Wang CL; Cheng Y; Liu SY; Zhang XC; Zhong WZ; Wu YL
    JTO Clin Res Rep; 2022 Jan; 3(1):100257. PubMed ID: 34977823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
    Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
    Li M; Li C; Ke L; Zhan M; Cheng M
    Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma.
    Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
    Ann Surg Oncol; 2017 Mar; 24(3):770-777. PubMed ID: 27696172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Clinicopathological Features and Prognosis between
    Li P; Gao Q; Jiang X; Zhan Z; Yan Q; Li Z; Huang C
    J Cancer; 2019; 10(1):61-71. PubMed ID: 30662526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.
    Zhou X; Cai L; Liu J; Hua X; Zhang Y; Zhao H; Wang B; Li B; Gai P
    Oncol Lett; 2018 Jul; 16(1):362-370. PubMed ID: 29928422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
    Lin CY; Wu YM; Hsieh MH; Wang CW; Wu CY; Chen YJ; Fang YF
    PLoS One; 2017; 12(10):e0186567. PubMed ID: 29065153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.